Alkem Reduces Prices of Denuril, Brand of Denosumab by 30% for the Treatment of Osteoporosis in Postmenopausal Women
One of India's leading drug makers, Alkem Labs, has recently announced the reduction in the price of Denosumab injection sold under the brand name Denuril.
Denuril, which contains Denosumab, is approved by DCGI for the treatment of osteoporosis in postmenopausal women.
It is available as a single-dose prefilled syringe containing 60 mg per 1 ml solution for subcutaneous injection.
In an endeavor to increase adherence and affordability of osteoporosis treatment, Alkem has slashed the price of its No. 1* prescribed Denosumab brand in India by more than 30%. Denuril injection, which was earlier costing INR 12499/-, will now be available at INR 8625/-.
Denosumab is a novel bone anti-resorptive agent used for the treatment of osteoporosis. It is a human IgG2 monoclonal antibody acting as Receptor Activator of Nuclear Factor kappa-Β Ligand (RANKL) inhibitor. It blocks osteoclast maturation and bone resorption.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.